Shen, Ye
Ou, Jinping
He, Bo
Yang, Jinmin
Liu, Huihui
Wang, Lihong
Wang, Bingjie
Gao, Liang
Yi, Chengqi
Peng, Jinying
Cen, Xinan
Funding for this research was provided by:
China Postdoctoral Science Foundation (2021M700234)
the National Natural Science Foundation of China (No. 22207003 to B.H., No 82072826 to J.P., No. 22207003 to B.H., No 82072826 to J.P.)
the National Key R&D Program (2020YFA0710401)
the Research and Demonstration Application of clinical diagnosis and treatment technology in the capital of China (Z191100006619026)
Article History
Received: 8 May 2022
Accepted: 26 September 2022
First Online: 11 October 2022
Declarations
:
: The study was conducted according to the guidelines of the Helsinki Declaration and was approved by the Ethics Committee of Peking University First Hospital. Written informed consent was obtained from all participants.
: Not applicable.
: B.X., A.Z., C.Z. and C.Y. are co-inventors on filed patents (PCT/CN2014/087479 and 201710111600.9) for the labeling strategies of 5fC and 5hmC.